Grade My Investments
HomeFree Stock Grades › TMDX

TransMedics Group, Inc. (TMDX) Stock Grade

TMDX · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$4.1B
P/E Ratio
21.7
Revenue Growth (YoY)
+37.1%
Net Margin
31.4%
Return on Equity
40.2%
Dividend Yield
None

About TransMedics Group, Inc.'s fundamentals

TransMedics Group is a medical device company with a market capitalization of $4.1 billion that is experiencing strong revenue growth of 37.1% year-over-year. The company demonstrates impressive profitability metrics, with a net profit margin of 31.4% and a return on equity of 40.2%, indicating efficient conversion of revenue to earnings and effective use of shareholder capital. Trading at a P/E ratio of 21.7, the company does not currently pay a dividend, suggesting management is reinvesting profits back into the business.

Track TMDX free — no credit card required. Live grade + monthly AI report →